I guess you're saying, Tat, that the Congressional Oversight Committees and FTC really "loved" the generic drug industry and its "appropriate" fees when it investigated 11 generic companies and their criminal, fraudulent activities accompanying their submissions to FDA for marketing approvals of their respective drugs. That was when OCI came into existence with one Office in ~ 1990, then 3 in 1993, NOW how many(?20 or so?) offices in cities in the United States and International locations. For that matter, the 9 justices of the Supreme Court on the bench in the 1940s didn't like "odious fraud" either, witness the opinionS in Hazel-Atlas, 322 U.S. 238(1944).
Care? The Federal and State governments are forking over Billions of $$$ to pay Medicare claims. Members of the public, young and old, are still experiencing death at rate of 1 every ~ 40 seconds from CVDs. The half-life of generic products is half that of Vascepa. And the Federal Circuit last year observed that Hikma's product has not been shown to be a "therapeutic" equivalent of Vascepa, and that FDA has not approved any CVD label submitted by Hikma--lack of record evidence that Hikma's product is effective treatment for CVDs, 104 F. 4th 1370(2024). Healthcare COST? Generics have yet to beat the $36 per year that I paid for Vascepa for many years prior to 7/1/2024
The Solicitor General cared enough in Hazel-Atlas to file a brief urging reversal of the 3rd Circuit Judgment that favored Hartford, about the largest glass bottle manufacturer.
How much did the FBI love Enron? How much did the FBI and OCI love Purdue(see December 2024 PRs for one example). Lobbying has not helped those entities, notwithstanding the taxes paid.
Market Data 
Markets 
AI
